Fallopian tube cancer metastatic

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
7 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
PARP inhibitor 3 substances
Platinum compound 1 substance
Anthracycline 1 substance
Antimetabolite 1 substance
Taxane 1 substance
Phase II: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase II

1 trial
  • AGO Research GmbH Commercial
    CARBOPLATIN; DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL; GEMCITABINE HYDROCHLORIDE; NIRAPARIB TOSILATE MONOHYDRATE; OLAPARIB; PACLITAXEL; RUCAPARIB
    2024-516959-40-00 1 country 2021 n=136
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AGO Research GmbH Commercial 1 Phase II 0
New trials by year
2021
1
← All indication landscapes